Sana Biotechnology Announces FDA Clearance oOf Investigational New Drug Application For SC291, A Hypoimmune-Modified, CD19-Directed Allogeneic CAR T Therapy, For Patients With Lupus Nephritis, Extrarenal Lupus, And ANCA-Associated Vasculitis
Portfolio Pulse from Benzinga Newsdesk
Sana Biotechnology, Inc. (NASDAQ:SANA) has received FDA clearance for its Investigational New Drug (IND) application to initiate a study of SC291, a hypoimmune-modified, CD19-directed allogeneic CAR T therapy, for patients with multiple B-cell mediated autoimmune diseases. The company plans to begin treating patients soon and expects to disclose initial safety and efficacy data in 2024.
November 09, 2023 | 10:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sana Biotechnology's FDA clearance for its IND application to study SC291 could potentially open new treatment avenues for autoimmune diseases. This development is likely to be viewed positively by investors.
The FDA clearance is a significant regulatory milestone for Sana Biotechnology, allowing it to proceed with its study of SC291. If successful, this could potentially lead to a new treatment for autoimmune diseases, which would likely increase the company's market value and positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100